Global Prostate Cancer Diagnostics Solution Market Growth (Status and Outlook) 2025-2031

The global Prostate Cancer Diagnostics Solution market size is predicted to grow from US$ 16320 million in 2025 to US$ 26030 million in 2031; it is expected to grow at a CAGR of 8.1% from 2025 to 2031.

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.Prostate cancer diagnostics solution refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.

United States market for Prostate Cancer Diagnostics Solution is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Prostate Cancer Diagnostics Solution is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Prostate Cancer Diagnostics Solution is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Prostate Cancer Diagnostics Solution players cover OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Prostate Cancer Diagnostics Solution Industry Forecast” looks at past sales and reviews total world Prostate Cancer Diagnostics Solution sales in 2024, providing a comprehensive analysis by region and market sector of projected Prostate Cancer Diagnostics Solution sales for 2025 through 2031. With Prostate Cancer Diagnostics Solution sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer Diagnostics Solution industry.

This Insight Report provides a comprehensive analysis of the global Prostate Cancer Diagnostics Solution landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Prostate Cancer Diagnostics Solution portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer Diagnostics Solution market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer Diagnostics Solution and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer Diagnostics Solution.

This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer Diagnostics Solution market by product type, application, key players and key regions and countries.

Segmentation by Type:

Tumor Biomarker Tests

Imaging

Biopsy

Other

Segmentation by Application:

Age Below 55

Age 55-75

Age Above 75

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

OPKO

Genomic Health

Abbott

Beckman Coulter

Siemens Healthcare

bioMeriux

Roche

MDx Health

DiaSorin

Myriad Genetics

Ambry Genetics

Please note: The report will take approximately 2 business days to prepare and deliver.